 10 eligible healthy volunteers will consecutively be allocated to 2 different dose groups of APOSECTM in a dose escalation scheme. The first 5 subjects in group A receive the low dose of APOSECTM 12.5106 lyophilized PBMCmL, the subsequent 5 subjects in group B will receive the high dose of APOSECTM 25106 lyophilized PBMCmL. Each volunteer will receive both Verum and Placebo on two artificial wounds on the inner upper non-dominant arm. The location of application of the Verum and Placebo proximal or distal is subjected to randomization. 